ArticleACS omega2026
Expanding the Range of Methods for Obtaining Diverse Representatives of Sulfonyl Phosphoramidate Oligonucleotides.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sulfonyl phosphoramidates are a class of internucleotide phosphate modifications that can be easily introduced during automatic solid-phase synthesis at the oxidation step using the Staudinger reaction with appropriate electron-deficient sulfonyl azides. Beyond altering the nature of the backbone, this class of modifications enables the introduction of various substituents within the structure of oligonucleotides. The existing method, which relies on a limited set of precursors, enables obtaining only a narrow range of representatives within this class. In this work, we report an approach for obtaining diverse representatives of the sulfonyl phosphoramidate class based on the introduction of commercially available building blocks with different functional groups into the structure of modification. The first proposed method involves the incorporation of chloroalkanesulfonyl azides, followed by the substitution of the chlorine atom with amine residues within the sulfonyl phosphoramidate derivative. Initial evaluation of a series of sulfonyl azides bearing terminal chlorine atoms on alkyl chains of varying lengths (C1-C3) led to the selection of 3-chloropropanesulfonyl azide as the most promising agent. A library of sulfonyl phosphoramidate derivatives bearing various amine residues, including bulky alkyl and polyamine moieties, was synthesized by using this azide. The introduction of reactive groups into a growing oligonucleotide chain enabled the multistep assembly of complex structures on a solid-phase support. In addition, the second method was proposed, involving the synthesis of sulfonyl azides already bearing amine residues for subsequent incorporation within oligonucleotides. This method can be implemented via three synthetic routes: introducing a lipophilic amine residue into the chloroalkanesulfonyl azide structure, synthesis of azides via sulfolactone ring-opening alkylation to obtain quaternized derivatives, and obtaining sulfamoyl azides. The developed methods are complementary, with one enabling the effective incorporation of functional residues that are difficult to introduce with the other two. The proposed approach enables a significant expansion of the set of sulfonyl phosphoramidate oligonucleotide derivatives by utilizing commercially available building blocks and straightforward reactions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.